Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

Volm, M; Rittgen, Werner; Drings, P.

doi:10.1038/bjc.1998.106

Cited by 155 publications

(77 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 However, the majority of previous works particularly emphasize that overexpression of cyclin A is a marker for poor prognosis in cancer. [24][25][26][27][28][29][30][31][32][33][34] There are 2 known isoforms of cyclin A. Cyclin A1 is the embryonal form of the protein, and its role is limited to male meiosis. 35 Cyclin A1 is also expressed in normal human testis and brain tissues, and in myeloid leuchemia cell lines.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of cyclin A in gastric cancer

Mrena

Wiksten

Kokkola

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

High level of cyclin A promotes carcinogenesis, and overexpression of cyclin A has been associated with poor prognosis of cancer patients. We validated the prognostic role of cyclin A in gastric cancer and evaluated its correlation with expression of an mRNA stability factor HuR. From 342 consecutive histologically confirmed gastric cancer patients were obtained 325 representative tissue specimens for cyclin A and 316 for HuR immunohistochemistry. Specimens were stained by cyclin A and HuR specific monoclonal antibodies. Nuclear immunostaining detected in 5% of the tumor cells was considered the cut-off for cyclin A positivity. Positive HuR immunoreactivity was scored as nuclear or cytoplasmic. Associations between scores, clinicopathological factors and survival were calculated by the v 2 -test, Fisher's exact test, Kaplan-Meier test and Cox model. Cyclin A detected in the nuclei of cancer cells was positive in 55% (179 of 325) of the specimens; 40% (127 of 316) of the specimens had cytoplasmic and 88% (279 of 316) nuclear immunoreactivity of HuR. Cyclin A expression was an independent prognostic factor for poor survival. Cyclin A immunoreactivity was associated with old age, high stage, proximal location of the tumor, intestinal type, noncurative resection, advanced penetration depth and with nodal metastases but not distant metastases. Furthermore, cyclin A expression was associated with cytoplasmic HuR expression, whereas no association with nuclear HuR was evident. Cyclin A is an independent prognostic factor in gastric cancer, and one mechanism for its overexpression may depend on cytoplasmic localization of HuR. ' 2006 Wiley-Liss, Inc.Key words: cyclin A; HuR; gastric cancer; prognosis; survival Cyclin A belongs to the cyclin protein superfamily, and it can activate two different cyclin-dependent kinases, CDK1 and CDK2. The level of cyclin A accumulates progressively throughout the interphase and disappears rapidly at the end of mitosis. Currently, phosphorylated cyclin A-CDK complex is suggested to play an important role in the initiation of DNA replication in the S phase. The precise function of cyclin A in mitosis is unclear, but it may prevent other cyclins from degradation. Overexpression of cyclin A and dysregulation of CDK-cyclin complexes promote tumor cell growth, which can be facilitated by phosphorylation of oncoproteins and tumor suppressors. 1,2 In gastric cancer, cell-cycle regulators have been connected with poor prognosis. For example, overexpression of cyclin E, which also binds to CDK2 and controls the G1-S transition, has been associated with aggressive disease. 3,4 Furthermore, strongly positive cyclin E in the tumors of patients having surgery with intent to cure is a marker of poor prognosis, and concurrent expression of cyclin E and p53 is an independent prognostic factor. 5 However, there are also reports indicating that cyclin E expression does not correlate with clinicopathological parameters, 6 or is associated with good prognosis. 7 Overexpression of cyclin A correlates with po...

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic significance of cyclin A in gastric cancer

Mrena

Wiksten

Kokkola

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…There are very few reports on cyclin A as a marker of proliferative cell fraction in cancer. In two recent studies by Volm, tumour tissue negativity for cyclin A expression predicted a favourable outcome in non-small-cell lung cancer patients (Volm et al, 1997(Volm et al, , 1998. We are aware of no previous studies correlating cyclin A score of the tumour to chemotherapy response.…”

mentioning

confidence: 92%

A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

et al. 1999

View full text Add to dashboard Cite

A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response ( P = 0.02) and longer progression-free survival time ( P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign

show abstract

“…Cyclin A is overexpressed in some hepatocellular carcinomas because it lacks a cyclin destruction box due to genomic insertion by the hepatitis B virus [3]. Recently, cyclin A alterations have also been identified in several tumors including squamous cell carcinomas of the lung [6,[19][20][21], oral cavity [11], esophagus [7] and uterine cervix [17].…”

mentioning

confidence: 99%

Amplification of the Cyclin A Gene in Canine and Feline Mammary Tumors.

Murakami

Tateyama

Rungsipipat

et al. 2000

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. DNAs from 33 canine mammary tumors and 8 feline mammary carcinomas were examined by Southern blot analysis to clarify genomic abnormalities of the cyclin A gene. Amplification of cyclin A was detected in 27.3% (9/33) of canine mammary tumors and 87.5% (7/8) of feline mammary carcinomas. It was suggested that amplification of cyclin A do not correlate directly with the tumorigenesis of canine mammary tumors, because there was no significant difference of incidence of cyclin A amplification between the benign and malignant tumors. In feline mammary carcinomas, the high frequency of cyclin A amplification raised the possibility that the amplification lead to the protein overexpression and play an important role in the tumorigenesis.KEY WORDS: amplification, cyclin A, mammary tumor.J. Vet. Med. Sci. 62(7): 783-787, 2000 Cyclins are prime cell cycle regulators that are central to the control of major checkpoints in eukaryotic cells. Cyclins are categorized into three types: A-type, B-type and G1 cyclins (C-, D-, and E-types), and are activated by forming a complex with cyclin dependent kinases (cdk) at various stages of the cell cycle. The involvement of several cyclins in human cancer has been recognized over the last several years [1-13, 15, 17-21].Cyclin A, a protein of 60 kDa, binds independently to cdk2 in S to G2 phase, and cdk2/cdc2 in G2 to M phase, leading to enzyme activation. Cyclin A is detectable in S phase, and increases during cell cycle progression to G2 phase. Cyclin A is overexpressed in some hepatocellular carcinomas because it lacks a cyclin destruction box due to genomic insertion by the hepatitis B virus [3]. Recently, cyclin A alterations have also been identified in several tumors including squamous cell carcinomas of the lung [6,[19][20][21], oral cavity [11], esophagus [7] and uterine cervix [17].We recently found that overexpression of cyclin A protein occurs frequently in canine malignant mammary tumors and feline mammary carcinomas. However, molecular analysis of cyclin A remains to be done. Therefore, we examined DNAs from canine and feline mammary tumors for amplification of the cyclin A gene using Southern blot analysis.The samples of 33 canine mammary tumors and 8 feline mammary carcinomas were collected during a 3-year period (1996)(1997)(1998) at the Department of Veterinary Pathology, Miyazaki University, Japan. For histopathology, the samples were fixed in 10% formalin, and paraffin sections were prepared and stained with hematoxylin and eosin (HE). The histological typing of the tumors is listed in Tables 1 and 3. Immunohistochemistry was performed by using EnvisionPolymer reagent (Dako Japan, Kyoto, Japan). The primary antibodies used were a rabbit polyclonal antibody against human cyclin A, a recombinant protein corresponding to amino acids 1-432 representing full-length cyclin A of human origin (H-432, Santa Cruz Biotech, U.S.A.). The chromogenic reaction was carried out with diaminobenzidine (Sigma, St. Louis, U.S.A.) and counterstained with Mayer's hematoxylin....

show abstract

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

Cited by 155 publications

References 10 publications

Prognostic significance of cyclin A in gastric cancer

Prognostic significance of cyclin A in gastric cancer

A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

Amplification of the Cyclin A Gene in Canine and Feline Mammary Tumors.

Contact Info

Product

Resources

About